All News
#ACR24: What Exactly do JAKs and TYKs Do?
Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly.… https://t.co/HkhZJBxDdO https://t.co/xYeSpHS2dD
Dr. John Cush RheumNow ( View Tweet)
COVID Associated Immune Disease
Dr. Len Calabrese reports on a session he participated in discussing if Covid-19 is associated or causal for autoimmune disease. Reporting from #ACR24
https://t.co/vFdlf9XVzf https://t.co/JhpglNVIt7
Links:
Dr. John Cush RheumNow ( View Tweet)
Hypoxia seems to exacerbate neutrophil activation by ANCA
- enhanced F-Actin polymerization
- enhanced NET formation
Could hypoxia predilection in certain tissues (kidney, lung) lead to the AAV phenotypic disease patterns?
@RheumNow #ACR24 https://t.co/KxaeMvkd2t
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Prior studies have shown that IFN is increased in non-lesional skin of SLE pts.
In this study, they found a ⬆️ expression of IFN stimulated genes (ISGs) in pts w/ a history of CLE.
No correlation w/ CLASI act & IFN scores but only few pts.
@RheumNow #ACR24 abs2678 https://t.co/cPT6yPkoCb
sheila RHEUMarampa ( View Tweet)
Late breaking abstract L17
CAR-NK Therapy for Refractory SLE.
In a trial of 20 severe SLE patients:
- 75% achieved LLDAS, 50% achieved DORIS remission at 6 months
- B cell reconstitution: 2–3 months post-treatment
- Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Mitochondria: the powerhouse of the cell—but the fuel behind gout flares?
#ACR24 @RheumNow https://t.co/lV4dovLV18
Akhil Sood MD AkhilSoodMD ( View Tweet)
In prelim analysis of this controlled clinical trial, SLE pts w/ active dse who weres given addtl NAC for 3 mos had significantly reduced dse activity.
Mechanism? NAC reduces rapamycin (mTOR) activation.
Common AEs: nausea, vomiting
@RheumNow #ACR24 abs2677 https://t.co/E4w2Qd7RwP
sheila RHEUMarampa ( View Tweet)
#Positive #RCT of #Nipocalimab a FcRn receptor inhibitor in #Sjogrens #Disease
👏Phase 2 +RCT
ESSSDAI and ESPRI both improved
🤷♀️what it means to lower #antibodoes #Ro #La
Excited for Phase 3 results
#ACRBest #ACR24 @RheumNow @ACRheum abst#2527 https://t.co/NeeYT7VR16
Janet Pope Janetbirdope ( View Tweet)
Autoantibody tests are everywhere, but how do we make sense of them? With the proper algorithms, can we go beyond interpretation to predicting autoimmunity before it develops?
Check out my article: Taking the AI out of AutoImmunity
https://t.co/d3ZNYWQaaQ
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Paraoxonase-1: Possible Biomarker for Progression to RA
Dr. Jonathan Kay discusses abstract 0464, Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population,… https://t.co/yhcCrrvjxH https://t.co/caf5dUvrOQ
Dr. John Cush RheumNow ( View Tweet)
Pathophysiological pathways in neuropsychiatric SLE. 2 components:
-Ischaemic
-Inflammatory
Zahi Touma @RheumNow #ACR24 https://t.co/wwlSSSpOIU
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Sullivan et al. Vasculitis in VEXAS. 81 patients. 27% vasculitis. Cutaneous SVV 20%, AAV 2.5%, cutaneous MVV 2.5%, LVV 2.5%. @RheumNow #ACR24 Abstr#2651 https://t.co/AV3RcuSKpV https://t.co/xrax025TzP
Richard Conway RichardPAConway ( View Tweet)
Sullivan et al. Vasculitis in VEXAS. 81 patients. 27% vasculitis. Cutaneous SVV 20%, AAV 2.5%, cutaneous MVV 2.5%, LVV 2.5%. @RheumNow #ACR24 Abstr#2651 https://t.co/AV3RcuSKpV https://t.co/xrax025TzP
Richard Conway RichardPAConway ( View Tweet)
Neuropsychiatric manifestations in SLE.
Susanne Benseler MD @RheumNow #ACR24 https://t.co/subiykC5Q4
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Diagnostic work up for neuropsychiatric SLE. Zahi Touma MD @RheumNow #ACR24 https://t.co/zLX1QHCaSu
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Very informative slide describing the 2 NPSLE pathogenetic pathways & their differences in mediators, mechanisms and NP events.
@RheumNow #ACR24
@rheumarhyme @theactiverheum https://t.co/D3XFDqxMBq
sheila RHEUMarampa ( View Tweet)
Why is there female predominance in #SLE - the extra X chromosome in females (XX) may not be inactivated properly- usually maintained by the long non-coding RNA #Xist
#ACR24 abst#2599 @RheumNow https://t.co/C9Qj5zSnpN
Bella Mehta bella_mehta ( View Tweet)
Abstract 1842: Off the shelf CAR T therapy
No lymphodepletion needed, delivering robust, targeted CD19+ B cell elimination in multiple in vitro assays
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Do pts w autoimmune disease (AID) respond differently to immune checkpoint inhibitors (ICI) & have different mortality or iRAE risk vs pts without AID?
Study of pts on ICI showed no significant difference in mortality in pts w & without pre-existing AID
Ab2532 #ACR24 @RheumNow https://t.co/suywDdGIB1
Mrinalini Dey DrMiniDey ( View Tweet)
Non-pharm tx in TAK - not something we always think about but…
Impressive effect of resistance exercise!!
Not just in symptoms but also inflammatory markers
Per Dr. Springer - even a stress ball could be enough for UE vascular health in these pt
@RheumNow #ACR24 https://t.co/3O46gobbMX
Brian Jaros, MD Dr_Brian_MD ( View Tweet)